Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | H3B-5942 + Temsirolimus |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
H3B-5942 | CS-0047696 | Hormone - Anti-estrogens 29 | H3B-5942 is a selective estrogen receptor covalent antagonist, which antagonizes wild-type and mutant forms of estrogen receptor alpha, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 29991605). | |
Temsirolimus | Torisel | CCI-779 | mTORC1 Inhibitor 9 | Torisel (temsirolimus) binds to FKBP-12 and allosterically inhibits mTOR (PMID: 16883305). Torisel (temsirolimus) is FDA approved for advanced renal cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|